tiprankstipranks
Advertisement
Advertisement
Arvinas price target raised to $18 from $16 at BTIG
PremiumThe FlyArvinas price target raised to $18 from $16 at BTIG
21d ago
Arvinas price target raised to $20 from $18 at Barclays
Premium
The Fly
Arvinas price target raised to $20 from $18 at Barclays
22d ago
Arvinas Faces Key Commercialization Risk as VEPPANU’s Success Hinges on Third‑Party Partner with Pfizer
Premium
Company Announcements
Arvinas Faces Key Commercialization Risk as VEPPANU’s Success Hinges on Third‑Party Partner with Pfizer
22d ago
Arvinas Grants Rigel Global Rights to VEPPANU Therapy
PremiumCompany AnnouncementsArvinas Grants Rigel Global Rights to VEPPANU Therapy
22d ago
Arvinas reports Q1 EPS (90c), consensus (63c)
Premium
The Fly
Arvinas reports Q1 EPS (90c), consensus (63c)
23d ago
Arvinas management to meet with BTIG
Premium
The Fly
Arvinas management to meet with BTIG
1M ago
Arvinas trading resumes
PremiumThe FlyArvinas trading resumes
1M ago
Arvinas announces FDA approval of VEPPANU for ESR1m, ER+/HER2- ABC
Premium
The Fly
Arvinas announces FDA approval of VEPPANU for ESR1m, ER+/HER2- ABC
1M ago
Arvinas trading halted, news pending
Premium
The Fly
Arvinas trading halted, news pending
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100